ReviewClinical parkinsonism & related disorders2026
EYE movement abnormalities in Parkinson's disease: optometric screening and rehabilitation.
Review in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is increasingly recognized as a multisystem disorder in which eye movement abnormalities provide important diagnostic and prognostic insights. Objective: This review synthesizes current evidence on oculomotor disturbances in PD, their clinical relevance, and their potential as biomarkers for early detection and disease monitoring. Methods: A structured narrative review was conducted using PubMed, Scopus, and Web of Science databases (up to July 2025). Although a systematic search strategy was applied, findings were synthesized narratively due to heterogeneity in study designs and outcomes. Results: Across studies, PD patients demonstrated prolonged saccadic latency, reduced vergence amplitudes, and impaired smooth pursuit, often correlating with disease severity. Several abnormalities were detectable in early-stage disease, preceding overt motor dysfunction. Interventions such as prisms, vergence exercises, and vision therapy showed potential benefits in alleviating diplopia and improving visual function. Quantitative eye-tracking measures emerged as promising objective biomarkers for disease monitoring. Discussion: Oculomotor assessment offers significant clinical implications, from supporting early diagnosis and differential recognition of parkinsonian syndromes to guiding rehabilitative strategies that enhance visual quality of life. However, heterogeneity of methodologies and limited longitudinal data constrain generalizability. Conclusions: Eye movement abnormalities represent a valuable, underutilized tool in PD care. Standardization of assessment protocols, integration with neuroimaging, and validation through large-scale longitudinal studies are essential to establish oculomotor metrics as reliable biomarkers for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.